Mirae Asset Global Investments Co., Ltd. Akero Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,065 shares of AKRO stock, worth $54,412. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,065
Previous 25,658
91.95%
Holding current value
$54,412
Previous $648,000
92.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AKRO
# of Institutions
168Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$181 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$147 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$143 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$138 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$135 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.22B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...